Development of safe and effective platform for lutetium-177-DOTATOC peptide receptor radionuclide treatment of neuroendocrine tumors or other tumors with high expression of somatostatin receptors

• Main Authors: TAN JINWEN, LEE HO-HOON
• Format: Patent
• Language: Chinese; English
• Published: 23.05.2025
• Subjects: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROMTHE BODY; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS

Provided herein are platforms for the treatment of neuroendocrine neoplasms by administering peptide receptor radionuclide therapies while causing minimal adverse side effects of the gastrointestinal tract and slowing renal dysfunction. According to the invention, the lutetium-177-DOTATOC is used as a radiotherapy agent, the arginine is used as a unique kidney protective agent, and the lutetium-177-DOTATOC and the arginine are respectively subjected to intravenous infusion into peripheral veins on different hands of a subject through individual infusion pipelines. After a subject receives the use method provided by the invention, the incidence rate of any adverse side effects of gastrointestinal tracts is remarkably reduced, and the kidney is also effectively protected. 在此提供了施用肽受体放射性核素疗法治疗神经内分泌肿瘤，同时引起最小化的胃肠道不良副作用和减缓肾功能恶化的平台。本发明使用镥-177-DOTATOC作为放射治疗剂，以及精氨酸作为唯一的肾脏保护剂，并透过个别的输注管线，将镥-177-DOTATOC和精氨酸分别对受试者的不同手上的外周静脉中进行静脉输注。受试者在接受根据本发明的使用方法后，其任何胃肠道不良副作用的发生率显著降低，而且肾脏也得到有效保护。